The RATIFY (CALGB 10603) trial was a landmark study demonstrating that the addition of the multikinase inhibitor midostaurin to standard “7 + 3” induction chemotherapy significantly improved overall survival (74.7 vs. 25.6 months) in younger patients with FLT3-mutated AML, establishing midostaurin as a standard component of frontline therapy [12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.